Pontifax
Venture capital · Herzeliya, Israel · Middle East and Africa
Pontifax is a healthcare-dedicated venture capital firm founded in 2004 with $1.2 billion under management. It establishes its own companies and partners with existing management, taking a hands-on approach to portfolio management.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcarebiotechpharmaceuticalsearly stagegrowth
Your fit with Pontifax
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPontifax lists 34 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (97%) and AI & Machine Learning (3%). 47% of its companies are based in United States. It invests most often alongside RA Capital, Kurma Partners and Triventures.
Counts come from funding rounds that name Pontifax, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Pontifax's whole history. Rounds on record name 2 companies; its own site lists 34. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 71th | 33 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 67th | 6% of companies confirmed by a round |
| Sector focus | 97th | 97% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 4 |
| Kurma Partners | 3 |
| Triventures | 3 |
| Altamont Pharmaceutical Holdings | 2 |
| BRM Capital | 2 |
| Novartis Venture Fund | 2 |
| Omega Funds | 2 |
| OurCrowd | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3294%
- No longer answers00%
- Points to another company26%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 97% | 15% |
| AI & Machine Learning | 3% | 18% |
Co-investor network
who it backs companies with, and who they back togetherCompare Pontifax head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Pontifax| Date | Company | Stage |
|---|---|---|
| 22 Jul 2026 | Series B | |
| 16 Oct 2025 | Series A | |
| 30 Sept 2025 | Series A |
Round details for Pontifax
Amounts, full round histories and every co-investor in Pontifax's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
34 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Abcuro develops therapies for autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| Adcendo is developing a new generation of antibody-drug conjugates to address cancers with high unmet medical need. | Healthcare & Biotech | Portfolio page | ||
| Adcytherix is building an antibody-drug conjugate powerhouse to advance patient-need-driven therapies | Healthcare & Biotech | Oct 2025Series A | Page + round | |
| Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| Anaveon develops next-generation biologics designed to selectively eliminate or reprogram pathogenic immune cells in autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| CathWorks develops a system that uses artificial intelligence and computational science to obtain physiologic information from routine angiograms | Healthcare & Biotech | Portfolio page | ||
| Climb Bio develops differentiated monoclonal antibodies for immune-mediated diseases. | Healthcare & Biotech | Portfolio page | ||
| Crystalys Therapeutics develops new therapeutics to address unmet medical needs, specifically for people living with gout. | Healthcare & Biotech | Sept 2025Series A · 2 rounds | Page + round | |
| CytoReason generates disease biology understanding from human molecular and clinical data to inform decisions across drug development. | Healthcare & Biotech | Portfolio page | ||
| Eloxx Pharmaceuticals develops a small molecule called exaluren to treat rare kidney diseases caused by nonsense mutations. | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides ophthalmic devices, including synthetic implants, to treat chronic corneal edema and related disorders. | Healthcare & Biotech | Portfolio page | ||
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | Portfolio page | ||
| Vascular Graft Solutions develops and provides technologies to improve coronary bypass surgery outcomes | Healthcare & Biotech | Portfolio page | ||
| Graviton Bioscience is pioneering safe and innovative therapies for patients with fibrotic, autoimmune, and CNS diseases. | Healthcare & Biotech | Portfolio page | ||
| IMEL Biotherapeutics is developing a novel mitochondrial replacement approach for cell-based therapies | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Kite Pharma develops cell therapies to treat cancer | Healthcare & Biotech | Portfolio page | ||
| LB Pharmaceuticals is developing medicines for brain disorders | Healthcare & Biotech | Portfolio page | ||
| Levation Pharma develops a treatment for Acquired Blepharoptosis | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- pontifax.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 30 Sept 2025
- Companies checked
- 34
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Pontifax's profile as data
Pull Pontifax's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/pontifax.com
# also
GET /v1/firms/pontifax.com/portfolio
GET /v1/firms/pontifax.com/coinvestors
GET /v1/firms/pontifax.com/news